MedPath
HSA Approval

HOVID GEFITINIB TABLETS 250 MG

SIN15984P

HOVID GEFITINIB TABLETS 250 MG

HOVID GEFITINIB TABLETS 250 MG

August 4, 2020

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L01XE02

xl 01 xe 02

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

Qilu Pharmaceutical (Hainan) Co. Ltd.

Active Ingredients

Gefitinib

250 mg

Gefitinib

Documents

Package Inserts

Hovid Gefitinib Tablets PI.pdf

Approved: July 8, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

HOVID GEFITINIB TABLETS 250 MG - HSA Approval | MedPath